Crescent Biopharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Crescent Biopharma, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 89% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-164.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 89% of Healthcare companies in United States.
Cash Cushion Ratio
+43%Cash, after subtracting all debt, equals 43% of its market value (net cash).
Higher than 75% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Crescent Biopharma, Inc. made a loss over the last year. Crescent Biopharma, Inc. owes $0.11 for every $1 it owns.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCrescent Biopharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.99The share price is 2.99 times Crescent Biopharma, Inc.'s book value per share, higher than 55% of Healthcare companies in United States.
Market cap
$488 MThe total market value of all of Crescent Biopharma, Inc.'s shares at today's price (share price × number of shares), larger than 54% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$163 MWhat Crescent Biopharma, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$4.39Net worth divided by the number of shares. The share price of $13.14 is 3.0 times this, which is the P/B above.
Owes vs Owns
0.11×Crescent Biopharma, Inc. owes $0.11 for every $1 it owns (low), lower than 86% of Healthcare companies in United States.
Dividend yield
NoneCrescent Biopharma, Inc. does not currently pay a dividend.
Profit margin
-1419.6%Crescent Biopharma, Inc. lost $1420 for every $100 of revenue.
Interest cover
Not coveredCrescent Biopharma, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashCrescent Biopharma, Inc. held $212 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Crescent Biopharma, Inc.: $488 M ÷ $163 M (30 Jun 2026) = 3.0.
How much does Crescent Biopharma, Inc. owe compared with what it owns?
Crescent Biopharma, Inc. owes $0.11 for every $1 it owns (low), lower than 86% of Healthcare companies in United States.
Does Crescent Biopharma, Inc. pay a dividend?
No. Crescent Biopharma, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.